ATP (Apple Tree Partners)的动态

Today Marengo Therapeutics announced?a clinical study collaboration with Gilead Sciences to evaluate Marengo’s Invikafusp alfa (STAR0602) and Gilead’s Trodelvy? in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers.? ? The collaboration will evaluate the combination of Marengo’s first-in-class TCR Vb selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead’s Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002). This innovative combination approach will leverage two unique modalities to target and potentially eradicate cancer cells. Read our press release to learn more:?https://lnkd.in/e6kX7Nhb

Partnership to Develop Next-Gen Radioligand Medicine for Rare Cancers!! ?? ?? !! Collaboration between Sanofi, Radiomedix, Inc. and Orano Med focuses specifically on the late-stage project, AlphaMedix?(212Pb-DOTAMTATE), which currently is being evaluated for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. AlphaMedixT?is a targeted alpha therapy (TAT) which consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. #AlphaMedix?has recently been granted Breakthrough Therapy Designation?in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) from the US FDA for patients who are na?ve to peptide-receptor radionuclide therapy. #sanofi #radiomedix #oranomed #competitiveintelligence #pharma #cancer

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has started treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort of its BOLSTER trial. CCA, also known as bile duct cancer, has a five-year survival rate less than 5%, highlighting the urgent need for new and effective treatments. The BOLSTER trial is a Phase 2a multi-center trial evaluating Lisata’s investigation drug certepetide in combination with standard-of-care treatments in patients with first- or second-line CCA. ? Certepetide is an investigational drug that enhances the delivery and effectiveness of anti-cancer treatments by improving drug penetration in tumors and... https://ow.ly/KLtg105IXo7

1. TransCode Therapeutics has begun dosing patients in a Phase 1 clinical trial for TTX-MC138, targeting metastatic cancers. 2. The trial is a multicenter, open-label, dose-escalation, and dose-expansion study focused on safety and tolerability. 3. TTX-MC138 is the first candidate aimed at targeting a molecule linked to metastatic disease, regardless of cancer location. 4. The therapy has potential benefits for various cancers, including breast, pancreatic, ovarian, colon, and lung cancers. 5. The trial consists of two phases: the dose-escalation phase and the dose-expansion phase. 6. The dose-escalation phase will assess safety and tolerability at increasing dose levels. 7. The dose-expansion phase will evaluate safety, tolerability, and anti-tumor activity in specific tumor types. 8. This trial represents a significant step toward developing effective treatments for metastatic cancers.

Alligator Bioscience AB has announced positive 18-month follow-up data from the OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study assessed the safety and efficacy of anti-CD40 mitazalimab in combination with standard of care chemotherapy mFOLFIRINOX, in previously untreated, chemotherapy na?ve pancreatic cancer patients. The data demonstrated 18-month survival rate of 36.2% in patients treated with mitazalimab in combination with mFOLFIRINOX, compared to 18.6% reported with FOLFIRINOX?alone. Alligator is continuing its preparations for the global Phase 3 registration study to evaluate mitazalimab in pancreatic cancer and the company remains on track to initiate the study in 2025.? https://lnkd.in/dVgcV5Fr

Last week, Medigene AG secured a patent protecting its T cell receptor directed against NY-ESO-1, aligning with analogous patents previously approved in the United States, Japan, South Korea, Taiwan, and Australia. Read here the PR: https://lnkd.in/dHrZtMsJ NY-ESO-1 is a a well-recognized and validated cancer-testis antigen, which is expressed in multiple tumor types varies with higher prevalence in metastatic vs. primary tumors. This TCR, alongside the PD1-41BB costimulatory switch protein, are the main element of Medigene AG lead program MDG1015, which is advancing towards the clinic. More information on MDG1015: https://lnkd.in/d6k_fakE As initial clinical indications for MDG1015 the Company selected gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma. More information around indication selection here: https://lnkd.in/dT6W2sPS #Platform2Patient

In advance of #ASCO, deepen your understanding of PD1/PD-L1 immune checkpoint inhibitors with our guide. Download our white paper for insights on the strengths, challenges, and potentials of inhibitors in diverse cancers. Stay tuned for more insightful #oncology resources from TFS as we approach ASCO. We invite you to stop by our booth #26149 to discuss your findings and insights with our authors and oncology experts. See you there! https://bit.ly/49e8ACe

Scancell Ltd Holdings PLC (AIM:SCLP, OTC:SCNLF)?has rolled out its roadmap for the next 18 months, which builds on the significant clinical progress made to date. An early milestone comes from the release of full cohort data for SCIB1 and iSCIB1+ (for melanoma)?in late 2024 and early 2025. The cancer immunotherapy specialist?also plans to launch a phase II/III registration trial for SCIB1 or iSCIB1+ in 2025. In the first stage of the phase II study of SCIB1, 11 out of 13 patients achieved at least a partial response, exceeding the 70% overall response rate the trial was configured to show. Additionally, data from the ModiFY study in renal cell carcinoma (RCC), using Modi-1 in combination with checkpoint inhibitors, is expected in the first half of 2025. The company is also focused on exploring partnering or out-licensing opportunities for its GlyMab?and AvidiMab?platforms.? The update was provided alongside results for... More at #Proactive #ProactiveInvestors https://ow.ly/HivJ105JH51

Ovarian cancer remains one of the deadliest cancers affecting women, often going undetected until it has reached an advanced stage, resulting in a poor five-year survival rate of only 50.9%.? ? https://lnkd.in/djGhVz9J? ? The pressing need to reduce ovarian cancer mortality emphasizes the importance of raising awareness and advancing oncology research. A promising new treatment developed by Nuvectis Pharma, Inc., NXP800, has just been granted FDA Orphan Drug Designation. This small molecule inhibitor targeting ARID1a-mutated ovarian cancer, is currently in a Phase 1b clinical trial evaluation, offering hope to ovarian cancer patients.? ? https://lnkd.in/eJ6iia7f?? #OvarianCancerAwareness?

Advancements in the Genitourinary Cancer Market! ASCO 2024 conference is poised to unveil groundbreaking advancements in the realm of genitourinary cancers, focusing on prostate cancer, bladder/urothelial cancer, and renal cell carcinoma. Leading pharmaceutical giants like Novartis, Pfizer, Merck, Arvinas, Astellas Pharma, Janssen Inc., Orion Pharma Ltd, and others are gearing up to present their latest research and developments, sparking significant interest and discussions throughout the event. A major highlight of ASCO 2024 will be CG Oncology's final results from the CORE-001 Phase II trial of cretostimogene in combination with KEYTRUDA. These findings are anticipated to signal a potential paradigm shift in the treatment landscape for NMIBC, offering newfound hope for patients unresponsive to traditional BCG therapy. To get exclusive insights on the genitourinary cancer treatment market, visit: https://lnkd.in/gnwgiqqt #ASCO2024 #GenitourinaryCancers #ProstateCancer #BladderCancer #RenalCellCarcinoma #PharmaResearch #Novartis #Pfizer #Merck #Arvinas #AstellasPharma #Janssen #OrionPharma #MedicalInnovations #CancerTreatment #ClinicalTrials #NMIBC #BCGTherapy #CancerResearch #HopeForPatients